Published in Mol Pharm on December 07, 2009
Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther (2013) 1.28
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol (2013) 0.82
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin Pharmacol Ther (2011) 0.80
Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. Sci Rep (2015) 0.79
Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOC(TM)) System. Toxicol Res (2015) 0.78
Proteoliposomes as tool for assaying membrane transporter functions and interactions with xenobiotics. Pharmaceutics (2013) 0.78
Expression of drug transporters in human kidney: impact of sex, age, and ethnicity. Biol Sex Differ (2015) 0.77
Assessment of Amino Acid/Drug Transporters for Renal Transport of [(18)F]Fluciclovine (anti-[(18)F]FACBC) in Vitro. Int J Mol Sci (2016) 0.75
Predicting drug-drug interactions through drug structural similarities and interaction networks incorporating pharmacokinetics and pharmacodynamics knowledge. J Cheminform (2017) 0.75
Transporters as Drug Targets in Neurological Diseases. Clin Pharmacol Ther (2016) 0.75
Interplay of drug metabolizing enzymes with cellular transporters. Wien Med Wochenschr (2014) 0.75
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics (2008) 1.72
Abnormal cortical networks in mild cognitive impairment and Alzheimer's disease. PLoS Comput Biol (2010) 1.72
Predicting drug-drug interactions: an FDA perspective. AAPS J (2009) 1.52
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos (2002) 1.26
Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med (2008) 1.20
Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol (2010) 1.18
CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet (2010) 1.12
Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm (2006) 1.11
Activation signal transduction by proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Hybridoma (Larchmt) (2009) 1.11
A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol (2009) 1.10
The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther (2003) 1.10
Increased cortical thickness in sports experts: a comparison of diving players with the controls. PLoS One (2011) 1.08
Retracted Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. BMC Musculoskelet Disord (2009) 1.07
Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther (2011) 1.07
Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol (2009) 1.05
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos (2012) 1.04
Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis (2006) 1.04
Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Lett (2010) 1.01
Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos (2004) 1.01
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol (2012) 1.01
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther (2005) 0.98
Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol (2003) 0.96
Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov (2011) 0.94
Tractography-based parcellation of the human left inferior parietal lobule. Neuroimage (2012) 0.92
Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol (2013) 0.91
Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies. Pharmacogenomics (2004) 0.90
A systematic comparison of cockcroft-gault and modification of diet in renal disease equations for classification of kidney dysfunction and dosage adjustment. Ann Pharmacother (2012) 0.90
Qualification of biomarkers for drug development in organ transplantation. Am J Transplant (2007) 0.90
Connectivity-based parcellation of the human posteromedial cortex. Cereb Cortex (2012) 0.90
Regional atrophy of the basal ganglia and thalamus in idiopathic generalized epilepsy. J Magn Reson Imaging (2011) 0.87
AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development. AAPS J (2011) 0.86
Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. J Clin Pharmacol (2012) 0.86
Dorsal visual pathway changes in patients with comitant extropia. PLoS One (2010) 0.86
Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. Biomark Med (2011) 0.85
Regulatory acceptance of toxicogenomics data. Environ Health Perspect (2004) 0.85
Botanical-drug interactions: a scientific perspective. Planta Med (2012) 0.85
Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model. J Cardiovasc Pharmacol (2010) 0.84
A robust and accurate algorithm for estimating the complexity of the cortical surface. J Neurosci Methods (2008) 0.84
A method of oligochip for single nucleotide polymorphism genotyping in the promoter region of the interleukin-1 beta gene and its clinical application. Oligonucleotides (2007) 0.83
The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity. Drug Metab Dispos (2013) 0.83
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis (2014) 0.82
Inhibitory effects of short hairpin RNA against caspase-8 on apoptosis of murine hepatoma Hepa1-6 cells. Biosci Trends (2009) 0.82
Effects of CD134 monoclonal antibody on hemolysis activities and expression of perforin in peripheral blood mononuclear cells of systemic lupus erythematosus patients. Hybridoma (Larchmt) (2007) 0.82
Dosage effects of BDNF Val66Met polymorphism on cortical surface area and functional connectivity. J Neurosci (2014) 0.81
The aberrant expression of stimulatory and inhibitory killer immunoglobulin-like receptors in NK- and NKT-cells contributes to lupus. Clin Lab (2014) 0.80
Diagnostic and prognostic significance of suPAR in traumatic brain injury. Neurol India (2014) 0.78
The value meal: effect of food on lapatinib bioavailability. J Clin Oncol (2007) 0.77
Association of an asporin repeat polymorphism with ankylosing spondylitis in Han Chinese population: a case-control study. Clin Invest Med (2010) 0.76
[Effects of large dose of Astragalus membranaceus on the dendritic cell induction of peripheral mononuclear cell and antigen presenting ability of dendritic cells in children with acute leukemia]. Zhongguo Zhong Xi Yi Jie He Za Zhi (2005) 0.76
Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population. Clin Exp Rheumatol (2011) 0.75
Risk of birth defects after use of acyclovir, valacyclovir, and famciclovir in the first trimester. JAMA (2010) 0.75
Tunnelling current recognition through core-satellite gold nanoparticles for ultrasensitive detection of copper ions. Chem Commun (Camb) (2015) 0.75
Design of aromatic helical polymers for STM visualization: imaging of single and double helices with a pattern of π-π stacking. Angew Chem Int Ed Engl (2015) 0.75
The effect of anti-human CD134 monoclonal antibody on phytohemagglutinin-induced mRNA expression of perforin in peripheral blood mononuclear cells. Cell Mol Immunol (2005) 0.75
Anti-TGF-beta1 antibody: an effective treatment for lung injury caused by paraquat in the future. Med Hypotheses (2007) 0.75
Serum IFN-λ1 is abnormally elevated in rheumatoid arthritis patients. Autoimmunity (2012) 0.75
Effect of antibody to CD134 on perforin-mediated cytolysis in human peripheral blood mononuclear cells. Hybridoma (Larchmt) (2006) 0.75
Expression and activation of proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Int Med Res (2009) 0.75
Effects of Ureaplasma urealyticum lipid-associated membrane proteins on rheumatoid arthritis synovial fibroblasts. J Int Med Res (2013) 0.75